The Proteasome Inhibitor Bortezomib Enhances ATRA-Induced Differentiation of Neuroblastoma Cells via the JNK Mitogen-Activated Protein Kinase Pathway
Authors:
Open Access
- 7 November 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27298
Abstract
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Differentiated human NBs are associated with better outcome and lower stage; induction of differentiation is considered to be therapeutically advantageous. All-trans retinoic acid (ATRA) has been shown to induce the differentiation of neuroblastoma (NB) cell lines. The proteasome inhibitor bortezomib inhibits cell growth and angiogenesis in NBs. Here, we investigated the synergistic effect between bortezomib and ATRA in inducing NB cell differentiation in different NB cell lines. Bortezomib combined with ATRA had a significantly enhanced antiproliferative effect. This inhibition was characterized by a synergistic increase in neuronal differentiation. At the same time, the combination therapy showed little neuronal toxicity which was assessed in primary cultures of rat cerebellar granule cells by the MTT assay, PI staining. The combination of bortezomib and ATRA triggered increased differentiation through the activation of proteins, including RARα, RARβ, RARγ, p-JNK and p21, compared with ATRA treatment alone. Using JNK inhibitor SP600125 to block JNK-dependent activity, the combination therapy-induced neuronal differentiation was partially attenuated. In addition, p21 shRNA had no effect on the combination therapy-induced neuronal differentiation. The in vivo antitumor activities were examined in human NB cell xenografts and GFP-labeled human NB cell xenografts. Treatment of human NB cell CHP126-bearing nude mice with ATRA plus bortezomib resulted in more significant tumor growth inhibition than mice treated with either drug alone. These findings provide the rationale for the development of a new therapeutic strategy for NB based on the pharmacological combination of ATRA and bortezomib.Keywords
This publication has 40 references indexed in Scilit:
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Ketamine Activates Cell Cycle Signaling and Apoptosis in the Neonatal Rat BrainAnesthesiology, 2010
- Transcriptional Repression of SKP2 Is Impaired in MYCN-Amplified NeuroblastomaCancer Research, 2010
- ATRA inhibits ceramide kinase transcription in a human neuroblastoma cell line, SH‐SY5Y cells: the role of COUP‐TFIJournal of Neurochemistry, 2009
- Differentiation therapy of leukemia: 3 decades of developmentBlood, 2009
- Effects of retinoic acids on the dendritic morphology of cultured hippocampal neuronsJournal of Neurochemistry, 2008
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Pediatric neuroblastomas: genetic and epigenetic ‘Danse Macabre’Gene, 2004
- Differentiation of neuroblastoma cells by phorbol esters and insulin-like growth factor 1 is associated with induction of retinoic acid receptor β gene expressionOncogene, 1999
- The RXR heterodimers and orphan receptorsCell, 1995